- Intersect ENT (XENT) expects Q4 revenue in the range of $27.7M to 28.1M (prior $27.0M to $28.6M) vs. a consensus of $27.65M.
- SINUVA recorded strong quarterly revenue of ~$2.5M vs. $1.7M in the prior quarter.
- VENSURE, for sinus balloon dilation, an acquired Fiagon product line, initiated U.S. sales with revenue of ~$0.3M.
- Cash, cash equivalents and restricted cash are expected to be ~$105M as of Dec. 31, 2020.
- 2021 outlook: Based on current and anticipated elective procedure volumes and referral trends, Intersect ENT expects to grow revenues in 2021 relative to 2019 despite the continuing uncertainties related to the impact of COVID-19.
- Press Release